Loading...
 

Volume 30, Issue 3, September 2019






Sign in to download the Issue in PDF format.

 


Mediterr J Rheumatol 2019;30(3):147-54
Lung Disease in Rheumatic Disorders
Authors Information

University of Newcastle upon Tyne, Newcastle, United Kingdom

References
  1. Shaw M, Collins B, Ho L, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev 2015;(24):1-16. [https://doi.org/10.1183/09059180.00008014] [PMID: 25726549]
  2. Thadani U, Iveson JM, Wright V. Cardiac tamponade, constrictive pericarditis and pericardial resection in rheumatoid arthritis. Medicine (Baltimore). 1975 May; 54(3):261-70. [https://doi.org/10.1097/00005792-197505000-00006] [PMID: 1143088]
  3. Kelly CA, Bourke J, Malcolm A, Griffiths ID. Chronic Pericardial Disease in Patients with Rheumatoid Arthritis: a Longitudinal Study. Q J Med 1990 May;75(277):461-70.
  4. Somaily M, Gladman D, Ibanez D, Urowitz M. Serositis In Systemic Lupus Erythematosus:  Prevalence, Recurrence, Treatment and Outcome. 2013 ACR/ARHP Annual Meeting Abstract Number: 1583
  5. Molokhia M, McKeigue P, Cuadrado M, Hughes G. Systemic lupus erythematosus in migrants from west Africa compared with Afro-Caribbean people in the UK. Lancet 2001 May 5;357(9266):1414-5. [https://doi.org/10.1016/S0140-6736(00)04580-3] [PMID: 11356443]
  6. Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006 Jun;35(6):368-78. [https://doi.org/10.1016/j.semarthrit.2006.03.002] [PMID: 16765714]
  7. Edwards M, Leak A. Pericardial effusions on anti-TNF therapy for rheumatoid arthritis - A drug side effect or uncontrolled systemic disease? Rheumatology (Oxford) 2009;48(3):316-7. [https://doi.org/10.1093/rheumatology/ken463] [PMID: 19106166]
  8. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases—from diagnosis to treatment. Rheumatology 2006;45(suppl4):iv22–iv25. [https://doi.org/10.1093/rheumatology/kel314] [PMID: 16980719]
  9. Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012;14:R213. [https://doi.org/10.1186/ar4051] [PMID: 23039366] [PMCID: PMC3580525]
  10. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088. [https://doi.org/10.1136/ard.62.11.1088] [PMID: 14583573] [PMCID: PMC1754353]
  11. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, et al. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012;39:276-85. [https://doi.org/10.3899/jrheum.110765] [PMID: 22247353]
  12. Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011;140:1016. [https://doi.org/10.1378/chest.10-2473] [PMID: 21474572]
  13. Kowal-Bielecka O, Avouac J, Pittrow D, et al. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010;37:105. [https://doi.org/10.1093/rheumatology/kex197] [PMID: 28992168] [PMCID: PMC5850595]
  14. Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol 2018;70:1820. [https://doi.org/10.1002/art.40560] [PMID: 29781586]
  15. Morrissey BM. Pathogenesis of bronchiectasis. Clin Chest Med 2007;28:289-96. [https://doi.org/10.1016/j.ccm.2007.02.014] [PMID: 17467548]
  16. Allain J, Saraux A, Guedes C, Valls I, Devauchelle V, Le Goff P. Prevalence of symptomatic bronchiectasis in patients with rheumatoid arthritis. Rev Rhum Engl Ed 1997;64:531-7. [PMID: 9385689]
  17. Mohd Noor N, Mohd Shahrir MS, Shahid MS, Abdul Manap R, Shahizon Azura AM, Azhar Shah S. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. Int J Rheum Dis 2009;12:136-44. [https://doi.org/10.1111/j.1756-185X.2009.01376.x] [PMID: 20374331]
  18. Remy-Jardin M, Remy J, Cortet B, Mauri F, Delcambre B. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994;193:375-82. [https://doi.org/10.1148/radiology.193.2.7972746] [PMID: 7972746]
  19. Perry E, Kelly C, de-Soyza A, Moullaali T, Eggleton P, Hutchinson D. Natural history, disease characteristics and autoantibody positivity in patients with bronchiectasis and RA: is the lung an initiating site of autoimmunity in rheumatoid arthritis? Rheumatology 2013;52: i76-7. [https://doi.org/10.1093/rheumatology/ket197]
  20. Kaushik VV, Hutchinson D, Desmond J, Lynch MP, Dawson JK. Association between bronchiectasis and smoking in patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:1001-2. [https://doi.org/10.1136/ard.2003.015123] [PMID: 15249329 ][PMCID: PMC1755104]
  21. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012;106:1591-9. [https://doi.org/10.1016/j.rmed.2012.07.006] [PMID: 22867979]
  22. Toussirot E, Despaux J, Wendling D. Increased frequency of HLA-DRB1*0401 in patients with RA and bronchiectasis. Ann Rheum Dis 2000;59:1002-3. [https://doi.org/10.1136/ard.59.12.1001b] [PMID: 11153480] [PMCID: PMC1753052]
  23. Yusof Y, Iqbal K, Emery P, Kelly C, Dass S. Safety of Rituximab in Patients with Rheumatoid Arthritis Associated with Bronchiectasis: Results from a Multicentre Cohort. Rheumatology 2016;55(suppl 1): i103–i104. [https://doi.org/10.1093/rheumatology/kew144.028]
  24. Schoenfeld SR, Castelino FV. Interstitial Lung Disease in Scleroderma. Rheum Dis Clin North Am 2015;41(2):237-48. [https://doi.org/10.1016/j.rdc.2014.12.005] [PMID: 25836640] [PMCID: PMC4385198]
  25. Ellman P, Ball RE. Rheumatoid disease with joint and pulmonary manifestations. BMJ 1948;2(4583):816-20.
  26. McDonagh J, Greaves M, Wright AR, Heycock C, Owen JP, Kelly C. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994;33:118-22. [https://doi.org/10.1093/rheumatology/33.2.118] [PMID: 8162474]
  27. Bongartz T, Nannini C, Medina-Velasquez Y, Achenbach SJ, Crowson CS, Ryu JH. Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis: A Population Based Study Arthritis Rheum 2010 Jun;62(6):1583-91. [https://doi.org/10.1002/art.27405] [PMID: 20155830] [PMCID: PMC4028137]
  28. Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62(8):722-7. [https://doi.org/10.1136/ard.62.8.722] [PMID: 12860726] [PMCID: PMC1754626]
  29. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatology 2014;53:1676-82. [https://doi.org/10.1093/rheumatology/keu165] [PMID: 24758887]
  30. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar Hemorrhage in Systemic Lupus Erythematosus. Chest 2000;118(4):1083-90.  [https://doi.org/10.1378/chest.118.4.1083] [PMID: 11035681]
  31. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren’s syndrome. Ann Rheum Dis 2000;59:709-12. [https://doi.org/10.1136/ard.59.9.709] [PMID: 10976085] [PMCID: PMC1753261]
  32. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976-87. [https://doi.org/10.1183/13993003.00150-2015] [PMID: 26160873]
  33. Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016;47:1767-75. [https://doi.org/10.1183/13993003.01565-2015] [PMID: 27103387] [PMCID: PMC5515625]
  34. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Resp Crit Care Med 2007;175(7):705-11. [https://doi.org/10.1183/13993003.01565-2015] [PMID: 27103387] [PMCID: PMC5515625]
  35. Iqbal K, Kelly CA. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 2015;7(6):247-67. [https://doi.org/10.1177/1759720X15612250] [PMID: 26622326] [PMCID: PMC4637848]
  36. Kelly CA. Interstitial Lung Disease in Rheumatoid Arthritis. Rheumatology 2014;53(suppl 1): i15. [https://doi.org/10.1093/rheumatology/keu066.002]
  37. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med 2012;366(21):1968-77. [https://doi.org/10.1056/NEJMoa1113354] [PMID: 22607134] [PMCID: PMC3422642]
  38. Scott K, Nisar M, Arthanari S, Woodhead F, PriceForbes A, Middleton D. OP254 Association between Steroid Therapy and Survival in Patients with Rheumatoid Arthritis Interstitial Lung Disease. Ann Rheum Dis 2014;73:157-8. [https://doi.org/10.1136/annrheumdis-2014-eular.1247]
  39. Brown M, Kelly C, Nisar M, Arthanari S, Woodhead F, PriceForbes A. SAT 0130 Rheumatoid Arthritis Related Interstitial Lung Disease – is There an Association between Disease Modifying anti Rheumatic Drugs and Survival? EULAR 2014: Scientific Abstract.  Ann Rheum Dis 2014;73:637.  [https://doi.org/10.1136/annrheumdis-2014-eular.1246]
  40. Koo B, Hong S, Kim Y, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med 2015;30(1):104-9. [https://doi.org/10.3904/kjim.2015.30.1.104] [PMID: 25589842] [PMCID: PMC4293548]
  41. Wagner SA, Mehta AC, Laber DA. Rituximab‐induced interstitial lung disease. Am J Hematol 2007;82(10):916-9. [https://doi.org/10.1002/ajh.20910] [PMID: 17597477]
  42. Druce KL, Iqbal K, Watson KD, Symmons DPM, Hyrich KL, Kelly C. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open 2017;3(1):e000473. [https://doi.org/10.1136/rmdopen-2017-000473] [PMID: 28955489] [PMCID: PMC5604605]
  43. Yusof Y, Kabia A, Lettieri G, Beirne P, Vital E, Dass S, Emery P. Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology 2017;56(8):1348-57. [https://doi.org/10.1093/rheumatology/kex072] [PMID: 28444364] [PMCID: PMC5850796]
  44. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford) 2017;3:344-50. [https://doi.org/10.1093/rheumatology/kew391] [PMID: 27940586] [PMCID: PMC6251572]
  45. Kelly C, Iqbal K. Comment on: Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology 2017;56(10):1824-5. [https://doi.org/10.1093/rheumatology/kex298]
  46. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit Care Med 2016 Jan 15;193(2):178-85. [https://doi.org/10.1164/rccm.201503-0562OC] [PMID: 26393389]
  47. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-92. [https://doi.org/10.1056/NEJMoa1402582] [PMID: 24836312]